共 315 条
[1]
Coiffier B(2017)Preparing for a new generation of biologic therapies: Understanding the development and potential of biosimilar cancer therapeutics Future Oncology 13 1-3
[2]
Declerck P(2017)The language of biosimilars: Clarification, definitions, and regulatory aspects Drugs 77 671-677
[3]
Danesi R(2017)Biosimilar biologic drugs: A new frontier in medical care Postgraduate Medicine 129 460-470
[4]
Petersel D(2012)Fc-fusion proteins: New developments and future perspectives EMBO Molecular Medicine 4 1015-1028
[5]
Jacobs I(2017)Fc1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: Immunological, biochemical and therapeutic properties Critical Reviews in Biotechnology 37 371-392
[6]
Geynisman DM(2007)FcRn: The neonatal Fc receptor comes of age Nature Reviews. Immunology 7 715-725
[7]
De Velasco G(2010)Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: A comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR Journal of Immunology 184 1968-1976
[8]
Sewell KL(2011)Efficient mucosal vaccination mediated by the neonatal Fc receptor Nature Biotechnology 29 158-163
[9]
Jacobs I(2021)CD47-targeted cancer immunogene therapy: Secreted SIRPa-Fc fusion protein eradicates tumors by macrophage and NK cell activation Molecular Therapy-Oncolytics 23 192-204
[10]
Czajkowsky DM(2015)Fc fusion as a platform technology: Potential for modulating immunogenicity Trends in Biotechnology 33 27-34